Clinical trials: Carcinoma Breast
Breast Cancer, Seroma
EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery
Negative pressure wound therapy (NPWT) could improve surgical outcomes and reduce complications like SSI, wound dehiscence and seroma in closed surgical wounds.
- Conditions
- Breast Cancer, Seroma, Wound Complication
- Trial name
- LAUREN (NCT05509829)
- Testing
- Negative pressure wound therapy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Zuyderland Medisch Centrum
Female Breast Cancer
Acupuncture for Joint Symptoms in Patients With Breast Cancer
Joint symptoms including stiffness, local pain and aches are common adverse reactions among breast cancer (BC) patients undergoing hormone treatments, while effective interventions for managing such symptoms have not been well…
- Trial name
- NCT03836872
- Testing
- Acupuncture
- Where
- China
- Volunteers
- 64 people
- Sponsor
- The Hong Kong Polytechnic University
Patient Relations, Nurse, Patient Satisfaction
Aromatherapy Methods in Reducing Anxiety Before Breast Biopsy
A breast biopsy is a cause for anxiety for most women when faced with a diagnosis of breast cancer. Physiological and psychological effects of breast biopsy may continue in the pre-biopsy and post-biopsy period.
- Conditions
- Patient Relations, Nurse, Patient Satisfaction, Anxiety State, Breast Cancer
- Trial name
- NCT05276505
- Testing
- Lavender Aromatherapy Tablet
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Acibadem University
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
UK Ibrance Patient Program (IPP) Study
What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients…
- Trial name
- ROIS (NCT03921866)
- Testing
- Palbociclib
- Where
- 8 sites in United Kingdom
- Volunteers
- 191 people
- Sponsor
- Pfizer
Invasive Breast Cancer, Ipsilateral Recurrence
Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse
Sentinel lymph node biopsy (SLNB) has become the standard procedure for staging of patients with clinically node-negative breast cancer.
- Conditions
- Invasive Breast Cancer, Ipsilateral Recurrence, Sentinel Lymph Node Biopsy
- Trial name
- FIGARO (NCT03630653)
- Testing
- Sentinel LN in breast cancer recurrence
- Where
- 9 sites in France
- Volunteers
- 50 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer
Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine
The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast.
- Trial name
- NCT01380353
- Testing
- Diclofenac epolamine patch
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
This phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04457596
- Testing
- Trastuzumab Emtansine, Tucatinib, Questionnaire Administration
- Where
- 1,176 sites in United States, Canada and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Breast Cancer
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors
1. To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated dose (MTD) of monotherapy.
- Trial name
- NCT03125746
- Testing
- LXI-15029, LXI-15029+Exemestane
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
HR-positive Breast Cancer
Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer
Treatment of hormone receptor (HR)-positive breast cancer with Aromatase Inhibitors (AIs) can lead to associated musculoskeletal pain and may cause patients to discontinue important treatment.
- Trial name
- NCT04205786
- Testing
- Vitamin B12, Blood collection, Brief Pain Inventory - Short Form survey
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancers, Liver Cancer
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the…
- Conditions
- Lung Cancers, Liver Cancer, Gastric Cancers, Colorectal, Cancer
- Trial name
- NCT06632886
- Testing
- AI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Guo ShiWei
Breast Cancer
Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors
The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between mild chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated…
- Trial name
- NEURO-BREAC-02 (NCT07604441)
- Testing
- Symptom-based scoring system
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Schleswig-Holstein
Breast Cancer
Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
This is a prospective, multi-center, randomized study designed to evaluate the clinical efficacy of cryotherapy combined with compression therapy in preventing albumin-paclitaxel induced peripheral neuropathy.
- Trial name
- NCT05341141
- Testing
- Frozen glove and sock, ddEC-ddT
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking University
Breast Cancer
Super-Resolution Ultrasound Microvascular Mapping for Non-Invasive Breast Cancer Molecular Subtyping: A Validated Nomogram
Purpose: This study aims to develop a non-invasive method to distinguish between luminal and non-luminal breast cancer subtypes using super-resolution ultrasound (SRUS).
- Trial name
- SRUS-Map (NCT07581054)
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Anhui Provincial Cancer Hospital
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Metastatic Solid Tumor, Ovarian Cancer
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
- Conditions
- Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD
- Trial name
- NCT07156253
- Testing
- SYN818 and Olaparib will be administered
- Where
- 2 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Breast Cancer Screening
A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue
Investigation of a tear-based, lab-developed biological test for breast cancer, as a supplemental tool to current screening recommendations for women with dense breast tissue will explore if a tear-based biological test can be…
- Trial name
- NCT05268224
- Testing
- Schirmer Strip
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Namida Lab
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by…
- Conditions
- Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
- Trial name
- NCT00725946
- Testing
- Iodine-124, PET/CT with Iodine-124
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Head and Neck Cancer, Breast Cancer
Evaluation of Improved Onboard Patient Imaging
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues.
- Conditions
- Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer
- Trial name
- NCT06187103
- Testing
- HyperSight Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Varian, a Siemens Healthineers Company
Metastatic Breast Cancer, Metastatic Solid Cancer
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment.
- Trial name
- HERMIA (NCT06369831)
- Testing
- 68Ga-NOTA-ABSCINT-HER2 PET/CT
- Where
- 7 sites in Austria, Belgium
- Volunteers
- 60 people
- Sponsor
- Abscint NV/SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.